氯膦酸二钠脂质体清除肝内巨噬细胞对CCl4诱导的慢性肝损伤大鼠门脉高压的影响*

doi:10.3969/j.issn.1672-5069.2020.04.008

摘要/Abstract

摘要： 目的观察氯膦酸二钠脂质体清除肝内巨噬细胞对CCl₄诱导的慢性肝损伤大鼠门脉高压的影响。方法随机将48只Wistar大鼠分为对照组和模型组,每组24只。采用皮下注射橄榄油和四氯化碳(CCl₄)法制备肝损伤模型。在实验d₇₀,再将每组分为2个亚组,分别经尾静脉注射磷酸盐缓冲液脂质体(PL)或氯膦酸二钠脂质体(CL)处理。在实验d₁₀₅,使用BL-420F生理机能实验系统测定大鼠肝脏在体门静脉压力,采用ELISA法检测血sCD163水平,采用免疫组化法检测肝组织CD163和诱导型一氧化氮合酶(iNOS)蛋白表达。结果在对照组内,CL处理大鼠血清sCD163水平为(798.6±61.9) pg/L,显著低于PL处理组[(848.3±26.2) pg/L,P＜0.05];在模型组内,CL处理大鼠肝脏指数和门静脉压力分别为(4.7±0.8)和(10.6±2.0) mmHg,显著低于PL处理组[分别为(5.6±1.3)和(12.4±2.7) mmHg,P＜0.05];模型组CL处理大鼠血清ALT、AST和sCD163水平分别为(69.9±21.4) U/L、(202.8±14.2) U/L和(980.1±122.3) pg/L,与PL处理大鼠比,均有显著性差异[分别为(97.8±39.6) U/L、(290.6±168.1) U/L和(1083.2±97.2) pg/L,P＜0.05];免疫组化结果显示,CL处理大鼠肝组织CD163和iNOS蛋白阳性表达较PL处理大鼠有不同程度的减弱。结论巨噬细胞参与门脉高压的发生和发展。清除巨噬细胞可降低门静脉压力。

关键词: 肝损伤, 门脉高压, 巨噬细胞, 氯膦酸二钠脂质体, 大鼠

Abstract: Objective To study the effect of depletion of intrahepatic macrophages by clodronate liposomes on CCl₄-induced portal hypertension in rats. Methods Forty-eight male Wistar rats were randomly divided into two groups with 24 in each, and the rats in the model group were injected with olive oil and carbon tetrachloride (CCl₄) twice a week, respectively. At d₇₀, the rats in the two groups were further divided into two subgroups. The rats in one subgroup were injected with phosphate buffered solution liposomes (PL), and in the other were dealt with clodronate liposomes (CL) intravenously through tail veins once a week to remove intrahepatic macrophages. At d₁₀₅, the portal pressure in vivo was measured by BL-420F physiological function experiment system, the serum level of sCD163 was assayed by ELISA, and the positive expression of CD163 and inducible nitric oxide synthase (iNOS) in the liver tissues were detected by immunohistochemistry staining. Results In the control groups, serum level of sCD163 was (798.6±61.9) pg/L in CL injected rats, significantly lower than in the PL injected rats[(848.3±26.2) pg/L, P<0.05]; in the model groups, the liver coefficients and portal vein pressure in CL-treated rats were (4.7±0.8) and (10.6±2.0) mmHg, respectively, significantly lower than [(5.6±1.3) and (12.4±2.7) mmHg, P <0.05]in PL-treated rats; serum levels of ALT, AST and sCD163 in CL-treated rats were (69.9±21.4) U/L, (202.8±14.2) U/L and (980.1±122.3) pg/L, respectively, which were significantly lower than[(97.8±39.6) U/L, (290.6±168.1) U/L and (1083.2±97.2) pg/L, P<0.05]in PL-treated rats; the Results of immunohistochemistry showed that the expression of CD163 and iNOS protein in the liver tissues in CL-treated rats were weaker than those in PL-treated rats. Conclusion Hepatic macrophages is involved in the pathogenesis and development of portal hypertension, and needs further investigation.

Key words: Liver injury, Portal hypertension, Macrophage, Clodronate liposomes, Rats

李爽, 刘金玉, 武晓玉, 王宏雅, 刘慧萍, 赵欣, 蔡大勇. 氯膦酸二钠脂质体清除肝内巨噬细胞对CCl₄诱导的慢性肝损伤大鼠门脉高压的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 484-487.

Li Shuang, Liu Jinyu, Wu Xiaoyu, et al. Depletion of intrahepatic macrophages by clodronate liposomes in rats with CCl₄-induced chronic liver injury and portal hypertension[J]. Journal of Practical Hepatology, 2020, 23(4): 484-487.

参考文献

[1]Kibrit J,Khan R,Jung BH,et al. Clinical assessment and management of portal hypertension. Semin Intervent Radiol,2018,35(3):153-159.
[2]卢琳琳. 门脉高压症的治疗进展. 实用肝脏病杂志,2012,6(15):597-598.
[3]Kimer N,Wiese S, Mo S,et al. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol,2016,10(8):961-969.
[4]Ju C,Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol,2016,13:316-327.
[5]Oishi Y,Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol,2018,30(11):511-528.
[6]Gomez Perdiguero E,Klapproth K Schulz C,et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature,2015,518(7540):547-551.
[7]Steib CJ. Kupffer cell activation and portal hypertension. Gut,2011,60(10):1307-1308.
[8]Rooijen NV,Kesteren-Hendrikx EV.“In vivo” depletion of macrophages by liposome-mediated “suicide”. Methods Enzymol,2003,373:3-16.
[9]Yokoyama Y,Xu H,Kresge N,et al. Role of Thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol,2003,284(3):G453-460.
[10]Vilaseca M,Guixe-Muntet S,Fernandez-Iglesias A,et al. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol,2018,11:1-19.
[11]Bosch J,Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatol Int,2018,12(Suppl 1):1-10.
[12]Holland-Fischer H,Gronbaek H,Sandahl TD,et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut,2011,60(10):1389-1393.
[13]Rooijen NV,Sanders A. Liposome mediated depletion of macrophages:mechanism of action, preparation of liposomes and applications. J Immunol Methods,1994,174(1-2):83-93.
[14]Bennett CL,Clausen BE. DC ablation in mice: promises, pitfalls, and challenges. Trends Immunol,2007,28(12):525-531.
[15]Weaver LK,Hintz-Goldstein KA,Pioli PA,et al.Pivotal advance:activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol,2006,80(1):26-35.
[16]Moestrup SK,Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response.Ann Med,2004,36(5):347-354.
[17]Jing W,Ye Y,Ying Y,et al. Expression of serum sCD163 in patients with liver diseases and inflammatory disorders.Int J Clin Exp Pathol,2015,8(7):8419-8425.
[18]Gronbaek H,Sandahl TD,Mortensen C,et al. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther,2012,36(2):173-180.
[19]Iwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase.Clin Mol Hepatol,2015,21(4):319.
[20]Kajita M,Murata T,Horiguchi K,et al. iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats.Am J Physiol Heart Circ Physiol,2010,300(3):H1021-1031.
[21]Zhao X, Deng B, Xu XY,et al. Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.World J Gastroenterol,2013,19(36):6069-6076.

氯膦酸二钠脂质体清除肝内巨噬细胞对CCl₄诱导的慢性肝损伤大鼠门脉高压的影响^*

Depletion of intrahepatic macrophages by clodronate liposomes in rats with CCl₄-induced chronic liver injury and portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨涓. 茵陈四苓颗粒对胆汁淤积性肝炎大鼠肝功能损害的改善作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 476-479.
[2]	汪可, 崔现平, 刘丽娟, 支庆江, 姜文营. 蓝莓花青素干预肝硬化大鼠肝组织凋亡蛋白表达的变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 480-483.
[3]	胡亦懿, 翟英姬, 梅迪华, 张志侨, 罗晓亮, 黄燕峰, 杜国平. 余甘子提取物对非酒精性脂肪性肝病大鼠外周血Treg细胞及肝组织LXRα/FAS通路表达的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 488-491.
[4]	何文昌, 张克恭, 赵凡惠, 郭芮杉, 高禄化, 黄长形, 王临旭. 290例药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 540-543.
[5]	唐晓飞,钟梦菊,沈海娟. 柚皮素脂质体对非酒精性脂肪性肝病大鼠脂质代谢的影响及机制研究[J]. 实用肝脏病杂志, 2020, 23(3): 328-331.
[6]	唐新亚,侯森,焦营营. 卡托普利对非酒精性脂肪性肝病大鼠肝细胞脂肪变性的影响[J]. 实用肝脏病杂志, 2020, 23(3): 332-335.
[7]	韩东,彭经纬,谢辉晋. 脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究[J]. 实用肝脏病杂志, 2020, 23(3): 409-412.
[8]	孙超, 范建高. 加强新型冠状病毒肺炎患者肝损伤的临床研究[J]. 实用肝脏病杂志, 2020, 23(2): 153-155.
[9]	姜佳丽, 李莉, 赵菲, 钟乐萍, 郭子皓, 张川, 展玉涛. 非酒精性脂肪性肝病大鼠肝组织Vaspin表达及其意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(2): 167-170.
[10]	黄橘村, 胡东辉, 张建军, 田德英. 慢病毒介导miR-203过表达对酒精性肝病大鼠肝损伤的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 171-174.
[11]	王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.
[12]	阿思根, 夏医君, 武慧军, 薛荣泉, 辛瑞强, 白斯古楞, 赵德芳. 脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 248-251.
[13]	王建辉, 郭红丹, 孔晶晶, 武希润. 抗结核药物致药物性肝损伤患者临床特点及其危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 58-61.
[14]	赵平, 黎涛, 谢吉良, 郑波. 早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 82-85.
[15]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.